CVS vs MEDP: fair value comparison
CVS Health Corporation and Medpace Holdings, Inc. · Updated 2026-08-31
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, CVS currently sits closer to the top of our discount ranking. MEDP carries the stronger quality grade.
| CVS | MEDP | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $93.06 | $573.29 |
| 12-month range | $72.49–$105.37 | $417.54–$594.02 |
| Sector rank | #88 of 113 Healthcare | #90 of 113 Healthcare |
| Quality grade | F | C |
| Leverage | Moderate | Low |
| Margin trend | Stable | — |
| Revenue growth | Modest | — |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: CVS fair value analysis · MEDP fair value analysis